Pharmaceuticals
Pharma - API & CRAMS
from 197 today
Piramal Pharma delivered better-than-expected revenue and EBITDA for 1QFY27, driven by a strong revival in the CDMO segment and broad-based momentum across all operating segments. We reiterate BUY with a target price of INR230.
Piramal Pharma posted robust Q1FY27 performance with revenue up 17.4% YoY and EBITDA margin expansion, driven by solid traction across CDMO and CHG segments. We raise our FY27/28E EBITDA by ~2-5%, retain BUY and raise our target price to INR 245.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
